Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system completed a pharmacokinetic (PK) study of the first...
View ArticleDuloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in...
The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first...
View ArticleBDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for...
BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful...
View ArticleActavis’ net revenue increases 40% to $2.66B in Q1 2014
Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.
View ArticleBreckenridge announces launch of Duloxetine Delayed-release Capsules
Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules.
View ArticleAVACEN Medical launches $2M campaign in response to positive outcomes of...
AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further company clinical trials and FDA applications.
View ArticleDepression drug can alleviate joint pain in postmenopausal women treated for...
A drug typically used to treat depression and anxiety can significantly reduce joint pain in postmenopausal women being treated for early stage breast cancer, according to new SWOG research to be...
View ArticleFunctional MRI brain scan may help predict patient’s response to...
A functional MRI brain scan may help predict which patients will respond positively to antidepressant therapy, according to a new study published in the journal Brain.
View ArticleFinding better way to quantify neuropathy symptoms and treatment efficacy
Most of the roughly 15.5 million cancer survivors in the U.S. receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy.
View ArticleStudy reveals link between popular pain medication and greater risk of...
Since its approval in 1995, the opioid tramadol (marketed as ConZip and Ultram) has become a widely prescribed remedy for osteoarthritis and other painful indications, in part because it presents a...
View Article
